PET findings after COVID-19 vaccination: “Keep Calm and Carry On”

Treglia, Giorgio; Cuzzocrea, Marco; Muoio, Barbara; Elzi, Luigia

doi:10.1007/s40336-021-00430-3

Cited by 13 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, increased radiopharmaceutical-uptake in the deltoid muscle corresponding to the vaccine inoculation site was also frequently described. Less commonly, diffuse splenic [ 18 F]FDG-uptake was reported [1]. These findings, related to [ 18 F]FDG-avidity of infectious tissue and inflammation, were previously observed after antiH1N1 and antiHPV vaccination [2][3][4].…”

Section: Introductionsupporting

confidence: 63%

The Day after Mass COVID-19 Vaccination: Higher Hypermetabolic Lymphadenopathy Detection on PET/CT and Impact on Oncologic Patients Management

Ferrari

Nappi

Santo

et al. 2021

Cancers

View full text Add to dashboard Cite

The widespread COVID-19 vaccination led to unexpected PET findings. Notably, axillary and interpectoral lymphadenopathies ipsilateral to the vaccine inoculation were observed. We aimed to assess the hypermetabolic lymphadenopathy (HLN) detection rate on PET/CT. Secondly, we investigated factors that might help in HLN differential diagnosis. A retrospective analysis on 1196 consecutive patients referred for a PET/CT was performed. All patients were asked about the date, type and site of vaccine injections. HLNs were recorded and categorized according to risk classes and SUVmax grades. A statistical analysis was performed to assess the correlation between HLN detection and different clinical/vaccine data. HLN detection rate was 15% and 27% in the No Vac- and vac-groups (p < 0.001), respectively. In the Vac-group, age (p < 0.001) and time interval from vaccine-to-PET (p = 0.010) were inversely correlated with HLN detection. Furthermore, SUVmax significantly changed during time intervals, with lower values beyond 20 days (p < 0.001). In the era of mass COVID-19 vaccination, a higher axillary and interpectoral lymphadenopathies detection ipsilateral to vaccine injection was observed. These PET findings can be wrongly interpreted, complicating cancer patients’ management. To minimize these pitfalls, a detailed vaccination anamnesis must be recorded and should take into account the appropriate PET schedule.

show abstract

Section: Introductionsupporting

confidence: 63%

The Day after Mass COVID-19 Vaccination: Higher Hypermetabolic Lymphadenopathy Detection on PET/CT and Impact on Oncologic Patients Management

Ferrari

Nappi

Santo

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Considering oncologic patients, the most informative study was conducted in a series of 728 patients having received the BNT162b2 mRNA vaccine ( 14 ). PET/CT revealed hypermetabolic lymph nodes in the axillary and supraclavicular regions draining the vaccine injection site in 36% of the subjects having received the first dose and 54% of those studied after the 2nd dose.…”

Section: Discussionmentioning

confidence: 99%

Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Moreover, during periods of infection, active fibrosis, and active granulomatous processes such as sarcoidosis, there is hypermetabolic uptake of FDG that often results in false-positive PET-CT scans for malignancy [ 16 ]. Since the initiation of the global COVID-19 vaccination programs, multiple studies have cited the occurrence of hypermetabolic axillary lymph nodes in patients after receiving the COVID-19 vaccine, which has complicated accurate diagnosis [ 11 , 17 , 18 ]. A meta-analysis including over 2000 patients undergoing 2-[18F]-FDG PET/CT revealed hyper-metabolic axillary lymph nodes with a prevalence of 37% after COVID-19 vaccination [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Metabolic Activity Assessment by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients after COVID-19 Vaccination

et al. 2022

View full text Add to dashboard Cite

In the following report, we describe 11 patients with various diagnoses and different treatment statuses (newly diagnosed, receiving treatment, or follow-up) of oncological diseases (breast, lymphoma, melanoma, and head and neck cancers). The patients underwent PET-CT for disease staging or follow-up and it was noted that all patients had areas of hypermetabolic uptake in the axillary lymph-nodes of the ipsilateral upper extremity where the Pfizer-BioNTech coronavirus (COVID-19) vaccine was administered. Following further investigations, including an ultrasound (US), biopsies and an examination of medical records, it was concluded that these findings were the result of the vaccination and not a progression of pre-existing disease.

show abstract

PET findings after COVID-19 vaccination: “Keep Calm and Carry On”

Cited by 13 publications

References 30 publications

The Day after Mass COVID-19 Vaccination: Higher Hypermetabolic Lymphadenopathy Detection on PET/CT and Impact on Oncologic Patients Management

The Day after Mass COVID-19 Vaccination: Higher Hypermetabolic Lymphadenopathy Detection on PET/CT and Impact on Oncologic Patients Management

Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report

Metabolic Activity Assessment by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients after COVID-19 Vaccination

Contact Info

Product

Resources

About